# Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

> **NCT06856499** · PHASE1 · RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 50 (estimated)

## Conditions studied

- Endometrioid Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Cirtuvivint
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT06856499
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-08
- **Primary completion:** 2027-07
- **Final completion:** 2029-07
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06856499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06856499, "Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06856499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*